How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

17,821 results for

"grant funding" or "obtaining grants" or "getting grants" or "grant awards" or (grants and "how to")

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

17721. Cryosurgery in Treating Patients With Liver Cancer or Liver Metastases

Study ID Numbers: 93-0092.cc NCI-V95-0657 ( Other Grant/Funding Number: National Cancer Institute ) First Posted: August 11, 2004 Last Update Posted: July 22, 2013 Last Verified: July 2013 Keywords provided by University of Colorado, Denver: localized unresectable adult primary liver cancer recurrent adult primary liver cancer liver metastases Additional relevant MeSH terms: Layout table for MeSH terms Liver Neoplasms Neoplasm Metastasis Digestive System Neoplasms Neoplasms by Site Neoplasms

1999 Clinical Trials

17722. 13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer

Information Go to Publications of Results: Layout table for additonal information Responsible Party: University of Colorado, Denver ClinicalTrials.gov Identifier: Other Study ID Numbers: 92-0382 NCI-V94-0506 ( Other Grant/Funding Number: National Cancer Institute ) First Posted: January 27, 2003 Last Update Posted: May 7, 2014 Last Verified: May 2014 Keywords provided by University of Colorado, Denver: non-small cell lung cancer small cell lung cancer drug/agent toxicity by tissue/organ Additional

1999 Clinical Trials

17723. Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)

: January 27, 2003 Last Update Posted : April 29, 2015 Sponsor: National Cancer Institute (NCI) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Radiofrequency interstitial tissue ablation may kill tumor cells by heating tumors to several degrees above body temperature. PURPOSE: This phase II trial is studying radiofrequency interstitial tissue ablation to see how well it works in treating patients with localized renal cell (...) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00019955 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Sponsors

2001 Clinical Trials

17724. Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy given after standard therapy to see how well it works in treating patients with stage III non-small cell lung cancer. Condition or disease Intervention/treatment Phase Lung Cancer Biological: mutant p53 peptide pulsed dendritic cell vaccine Procedure: adjuvant therapy Phase 2 (...) the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00019929 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 United States, Tennessee Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States, 37232-6838 Sponsors and Collaborators National Cancer

2001 Clinical Trials

17725. Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer

. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and interleukin-2 and to see how well they work in treating women with stage IV, recurrent, or progressive breast or ovarian cancer. Condition or disease Intervention/treatment Phase Breast Cancer Ovarian Cancer Biological: aldesleukin Biological: p53 peptide vaccine Procedure: in vitro-treated peripheral blood stem cell transplantation Phase 1 Phase 2 Detailed Description: OBJECTIVES: Determine whether (...) information United States, Maryland NCI - Center for Cancer Research Bethesda, Maryland, United States, 20889 Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Sponsors and Collaborators National Cancer Institute (NCI) Investigators Layout table for investigator information Principal Investigator: Samir N. Khleif, MD National Cancer Institute (NCI) More Information Go to Layout table for additonal information ClinicalTrials.gov Identifier

2001 Clinical Trials

17726. Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma

(NCI) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed during surgery. Giving chemotherapy after surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving chemotherapy before and after surgery works (...) information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00019864 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office Bethesda, Maryland, United States, 20892-1182 United States, Oklahoma Oklahoma University Cancer Institute Oklahoma City, Oklahoma, United States, 73104 United States, Texas Cook Children's Medical Center - Fort Worth Fort Worth, Texas

2001 Clinical Trials

17727. Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases

is studying how well isolated hepatic perfusion with melphalan works in treating patients with primary unresectable liver cancer or liver metastases. Condition or disease Intervention/treatment Phase Colorectal Cancer Islet Cell Tumor Liver Cancer Metastatic Cancer Neuroendocrine Carcinoma Drug: isolated perfusion Drug: melphalan Procedure: conventional surgery Phase 2 Detailed Description: OBJECTIVES: Determine response rate, duration of response, and patterns of recurrence in patients with primary (...) of anticoagulants No concurrent immunosuppressive therapy Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00019786 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support

2001 Clinical Trials

17728. Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer

thalidomide after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase II trial is studying surgery and thalidomide to see how well they work compared to surgery alone in treating patients with recurrent or metastatic colorectal cancer. Condition or disease Intervention/treatment Phase Colorectal Cancer Drug: thalidomide Procedure: adjuvant therapy Other: Placebo Phase 2 Detailed Description: OBJECTIVES: Compare the disease-free survival probability in patients with previously (...) , Maryland, United States, 20817 Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 United States, North Carolina Wake Forest University Comprehensive Cancer Center Winston-Salem, North Carolina, United States, 27157-1096 United States, Ohio Charles M. Barrett Cancer Center at University Hospital Cincinnati, Ohio, United States, 45267-0558 United States, Pennsylvania UPMC Cancer Center at UPMC Presbyterian Pittsburgh, Pennsylvania, United

2001 Clinical Trials

17729. PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy

: National Institutes of Health Clinical Center (CC) Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): National Institutes of Health Clinical Center (CC) Study Details Study Description Go to Brief Summary: RATIONALE: Diagnostic procedures, such as PET and MRI scans, may help to measure a patient's response to treatment. PURPOSE: This diagnostic trial is studying how well PET and/or MRI scans work in assessing changes in tumor blood supply in patients receiving (...) Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00019565 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical

2001 Clinical Trials

17730. Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma

Go to Layout table for additonal information Responsible Party: Fox Chase Cancer Center ClinicalTrials.gov Identifier: Other Study ID Numbers: CDR0000068772 FCCC-95043 ( Other Identifier: Fox Chase Cancer Center ) NCI-G01-1985 ( Other Grant/Funding Number: NCI ) First Posted: March 11, 2004 Last Update Posted: July 10, 2013 Last Verified: July 2013 Keywords provided by Fox Chase Cancer Center: stage I multiple myeloma stage II multiple myeloma stage III multiple myeloma Additional relevant MeSH

2001 Clinical Trials

17731. Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Institute (NCI) Information provided by: National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: RATIONALE: Vaccines made from white blood cells treated with antigens may make the body build an immune response to kill melanoma cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Combining vaccine therapy with interleukin-2 may kill more melanoma cells. PURPOSE: This phase I/II trial is studying the side effects and how well giving vaccine (...) number): NCT00019214 Locations Layout table for location information United States, Maryland Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Sponsors and Collaborators National Cancer Institute (NCI) Investigators Layout table for investigator information Study Chair: James C. Yang, MD NCI - Surgery Branch More Information Go to Layout table for additonal information ClinicalTrials.gov Identifier: Obsolete Identifiers: NCT00001558

2001 Clinical Trials

17732. Patterns and Natural History of Insulin Secretion in Islet Cell Transplant Recipients and Controls

). Recruitment status was: Active, not recruiting First Posted : July 5, 2001 Last Update Posted : June 28, 2005 Sponsor: National Center for Research Resources (NCRR) Collaborator: Juvenile Diabetes Research Foundation Information provided by: National Center for Research Resources (NCRR) Study Details Study Description Go to Brief Summary: This grant is to study patients that have received a kidney transplant AND an Islet Cell transplant and to discover how the transplant is functioning. We will seek (...) to have several patients who have had a kidney transplant but do NOT have either type of diabetes. These patients will serve as the "control group" since they will also be on immunosuppressive medications but are not affected by abnormal blood sugars. This will allow investigators to develop an understanding of how these immunosuppressive medications affect glucose metabolism (blood sugar levels) and insulin utilization (how the body uses insulin). Condition or disease Diabetes Mellitus Detailed

2001 Clinical Trials

17733. S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach

): NCT00004233 Sponsors and Collaborators Southwest Oncology Group National Cancer Institute (NCI) Investigators Layout table for investigator information Study Chair: James H. Doroshow, MD City of Hope Comprehensive Cancer Center More Information Go to Publications of Results: Layout table for additonal information Responsible Party: Laurence H. Baker, D.O.; Group Chair, Southwest Oncology Group ClinicalTrials.gov Identifier: Other Study ID Numbers: CDR0000067477 CA32102 ( Other Grant/Funding Number

2000 Clinical Trials

17734. Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

Identifier: Other Study ID Numbers: KL4-MAS-03 FD-R-001938 ( Other Grant/Funding Number: US Department of Health and Human Services ) First Posted: October 19, 1999 Results First Posted: May 1, 2012 Last Update Posted: May 3, 2012 Last Verified: May 2012 Keywords provided by Windtree Therapeutics: cardiovascular and respiratory diseases meconium aspiration syndrome rare disease Additional relevant MeSH terms: Layout table for MeSH terms Meconium Aspiration Syndrome Lung Injury Lung Diseases Respiratory

1999 Clinical Trials

17735. Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis

631-444-1754 Sponsors and Collaborators Stony Brook University State University of New York FDA Office of Orphan Products Development Investigators Layout table for investigator information Study Chair: Sami I. Said State University of New York More Information Go to Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: 199/14275 SUNY-SB-FDR001488 SUNY-SB-96-077 SUNY-SB-98-2606 FD-R-0001488 ( Other Grant/Funding Number: FDA Orphan Drug Products ) First

1999 Clinical Trials

17736. Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

information Responsible Party: Gerald Raymond, Associate Professor of Neurology, Johns Hopkins University School of Medicine, Hugo W. Moser Research Institute at Kennedy Krieger, Inc. ClinicalTrials.gov Identifier: Other Study ID Numbers: 199/13312 Nutricia-Loma Linda ( Other Grant/Funding Number: Nutricia-Loma Linda ) KKI-FDR000685 ( Other Identifier: FDA ) First Posted: October 19, 1999 Last Update Posted: September 18, 2014 Last Verified: September 2014 Keywords provided by Gerald Raymond, Hugo W

1999 Clinical Trials

17737. Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer

is studying the best dose of ixabepilone when given together with estramustine and to see how well giving ixabepilone together with estramustine works compared to ixabepilone alone in treating patients with progressive prostate cancer. Condition or disease Intervention/treatment Phase Prostate Cancer Drug: estramustine phosphate sodium Drug: ixabepilone Phase 1 Phase 2 Detailed Description: OBJECTIVES: Determine the maximum tolerated dose of ixabepilone combined with estramustine in patients (...) , Horse-Grant D, et al.: Epothilone B analogue (BMS-247550) with estramustine phosphate (EMP) in patients (pts) with progressive castrate-metastatic prostate cancer (PC). [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-732, 184a, 2002. Layout table for additonal information ClinicalTrials.gov Identifier: Other Study ID Numbers: CDR0000068935 MSKCC-01064 MSKCC-01064A NCI-3634 First Posted: January 27, 2003 Last Update Posted: June 24, 2013 Last Verified: November 2005 Keywords

2001 Clinical Trials

17738. Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal Cancer

Chase Cancer Center National Cancer Institute (NCI) Investigators Layout table for investigator information Study Chair: Neal J. Meropol, MD Fox Chase Cancer Center More Information Go to Layout table for additonal information Responsible Party: Fox Chase Cancer Center ClinicalTrials.gov Identifier: Other Study ID Numbers: FCCC-98026 NCI-T97-0051 ( Other Grant/Funding Number: NCI ) First Posted: June 9, 2004 Last Update Posted: July 11, 2013 Last Verified: July 2013 Keywords provided by Fox Chase

2000 Clinical Trials

17739. Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)

PTSD symptoms on a frequency/severity scale corresponding to the DSM-IV symptom criteria. The measure has a total score range from 0 to 51, with higher scores indicating more severe PTSD symptoms. Drinking Timeline Follow-back Interview (TFBI) [ Time Frame: Week 0 (Pretreatment), Week 24 (Posttreatment), Week 52 (Follow-up) ] The TFBI is an interview that utilizes a calendar method to assess when and how much alcohol was consumed by the participant. At Week 0 (Pretreatment), Week 24 (Posttreatment (...) information Principal Investigator: Edna B. Foa, PhD University of Pennsylvania More Information Go to Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Layout table for additonal information Responsible Party: University of Pennsylvania ClinicalTrials.gov Identifier: Other Study ID Numbers: NIAAAFOA12428 NIH grant R01-AA-012428 First Posted: November 9, 2000 Results First Posted: April 21, 2017 Last Update Posted: April 21, 2017 Last Verified: March 2017

2000 Clinical Trials

17740. Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

) DUMC-1408-98-9R1 ( Other Identifier: Duke University IRB ) DUMC-1533-00-8R3 ( Other Identifier: Duke University IRB ) DUMC-1570-99-9R2 ( Other Identifier: Duke University IRB ) DUMC-97107 ( Other Identifier: Duke University Cancer Protocol Committee ) 5P0NS20023 ( Other Grant/Funding Number: National Cancer Institute ) NCI-G98-1472 ( Other Grant/Funding Number: National Cancer Institute ) CDR0000066522 ( Other Identifier: National Cancer Institute Record Identifier ) First Posted: April 30, 2003

1999 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>